Metabolic Health Solutions Secures $129M to Revolutionize Global Metabolic Care

Metabolic Health Solutions (MHS), a pioneer in metabolic health innovation, is thrilled to announce the successful raising of $129,000,000 in its latest funding round. This significant investment will accelerate the company’s mission to revolutionize the measurement, monitoring, and management of metabolic health worldwide. Headquartered in Perth, Western Australia, MHS has consistently set new benchmarks with its lead technology, ECAL™, the world’s first portable metabolic monitor designed specifically for clinical practice, and is proud to hold both ISO13485 certification and a CE mark. The funding will be strategically directed towards expanding the clinical adoption of ECAL™ and bolstering the development of ENABLE™, an innovative digital health platform that bridges the communication gap between practitioners and patients globally. With a seasoned international management team at the helm and growing customer bases in Australia, Europe, and Asia, MHS is in a prime position to further refine and deploy clinical protocols that use ECAL™ to provide individualized lifestyle interventions. These protocols have already been piloted among 1500 Western Australians, addressing common metabolic disorders with personalized care plans that monitor metabolic rate, body composition, energy substrate usage, and hormone status. The new funds will not only support further clinical trials and research but will also enhance strategies for global expansion, ensuring that primary care providers, specialist practitioners, and university departments worldwide have seamless access to this transformative technology. This funding milestone represents a crucial step forward in MHS’s mission to empower healthcare professionals with the tools necessary for delivering precise, proactive care in metabolic health.